Inotiv shares slide 6.8% as cash crunch deepens amid mounting legal costs
Drug discovery services provider misses earnings estimates with cash position deteriorating 42% to $12.7 million against $405.8 million debt load
Inotiv Inc. shares fell 6.8% on Monday after the drug discovery services provider reported quarterly results that revealed a deteriorating cash position and widening losses, raising fresh concerns about the company's ability to manage a heavy debt load amid ongoing legal obligations.
The Indiana-based company reported fiscal first quarter revenue of $120.9 million, a modest 0.8% increase from the prior year but well short of analyst expectations of $126.5 million. More troubling for investors was the company's adjusted earnings per share of negative 83 cents, significantly worse than the 51-cent loss analysts had anticipated.
Net losses widened to $28.4 million, or 23.5% of revenue, compared with $27.6 million a year earlier. The company's cash position deteriorated sharply to $12.7 million at quarter-end, down 42% from $21.7 million just three months prior, while total debt stood at $405.8 million.
The liquidity squeeze comes as Inotiv continues to grapple with substantial legal costs stemming from multiple regulatory actions and litigation. The company recorded $2.2 million in "other unusual, third-party costs" during the quarter, primarily related to Resolution Agreement and Plea Agreement legal fees and the 2025 Cybersecurity Incident.
In June 2024, Inotiv reached an agreement with the U.S. Department of Justice to resolve a criminal investigation into animal welfare and environmental violations at a canine breeding facility it acquired in 2021. The settlement requires the company to pay $22 million in fines over four years, with the first payment due in June 2025, and invest at least $7 million in facility improvements.
Separately, the company is navigating the fallout from a August 2025 cybersecurity incident that compromised the personal information of approximately 9,500 individuals and led to multiple class-action lawsuits. Inotiv has also agreed to an $8.75 million settlement to resolve a securities class action lawsuit, subject to court approval.
"The company continued to execute on operational and financial priorities with a focus on client service and margin discipline," said Robert Leasure Jr., Inotiv's president and chief executive officer, in a statement. He highlighted "encouraging demand trends, particularly within the DSA segment" and progress in building "durable client relationships and recurring business."
The company's results indeed revealed a tale of two segments. Revenue from the Discovery & Safety Assessment (DSA) unit increased 12% to $48.0 million, driven by higher discovery and translational sciences revenue. The DSA backlog grew to $145.4 million, up from $138.2 million at the end of the prior quarter, with a book-to-bill ratio of 1.16x.
However, the Research Models & Services (RMS) segment declined 5.4% to $72.9 million, primarily due to lower non-human primate volumes sold, despite higher average selling prices. The company did not provide specific financial guidance for the remainder of fiscal 2026.
Inotiv's market capitalization has plummeted to approximately $13.4 million, with the stock trading near its 52-week low of 38 cents. Despite the challenging fundamentals, analysts maintain an average price target of $3.00, suggesting substantial upside if the company can stabilize its operations and reduce its legal overhang.
Institutional ownership stands at approximately 24%, with top holders including Vanguard Group and Balyasny Asset Management, according to recent filings. The company's high debt burden of $405.8 million against its sharply reduced cash position has become the primary concern for investors, particularly as it faces ongoing legal settlement payments and rising interest costs.